Development and pharmacological characterization of conformationally constrained urotensin II-related peptide agonists.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2013-11-26

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm401153jPMID 24251366
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The differential extraction and immunoluminometric assay of Urotensin II and Urotensin-related peptide in heart failure.

  2013cited by this paper
• Discovery of new antagonists aimed at discriminating UII and URP‐mediated biological activities: insight into UII and URP receptor activation

  2013cited by this paper
• New insight into the binding mode of peptides at urotensin‐II receptor by Trp‐constrained analogues of P5U and urantide

  2013cited by this paper
• The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats

  2013cited by this paper
• Urotensin Inhibition with Palosuran Could Be a Promising Alternative in Pulmonary Arterial Hypertension

  2012cited by this paper
• Genetic and Pharmacological Manipulation of Urotensin II Ameliorate the Metabolic and Atherosclerosis Sequalae in Mice

  2012cited by this paper
• Biochemical and pharmacological characterization of nuclear urotensin‐II binding sites in rat heart

  2012cited by this paper
• Urocontrin, a novel UT receptor ligand with a unique pharmacological profile.

  2012cited by this paper
• Therapeutic potential of β-arrestin- and G protein-biased agonists.

  2011cited by this paper
• Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects.

  2011cited by this paper
• Urantide alleviates monocrotaline induced pulmonary arterial hypertension in Wistar rats.

  2011cited by this paper
• Urotensin II receptor antagonist attenuates monocrotaline-induced cardiac hypertrophy in rats.

  2010cited by this paper
• Role of urotensin II in health and disease.

  2010cited by this paper
• Urotensin II, from fish to human

  2010cited by this paper
• Urotensin-II receptor modulators as potential drugs.

  2010cited by this paper
• The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation.

  2010cited by this paper
• A novel solid phase approach to Aia‐containing peptides

  2009cited by this paper
• CHARMM: The biomolecular simulation program

  2009cited by this paper
• Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: comparison with endothelin-1.

  2009cited by this paper
• Structure–activity relationship study on Tyr9 of urotensin-II(4–11): Identification of a partial agonist of the UT receptor

  2009cited by this paper
• Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues.

  2009cited by this paper
• Urotensin II induces phenotypic differentiation, migration, and collagen synthesis of adventitial fibroblasts from rat aorta

  2008cited by this paper
• Structure-activity relationships of urotensin II and URP.

  2008cited by this paper
• [Orn5]URP acts as a pure antagonist of urotensinergic receptors in rat cortical astrocytes.

  2008cited by this paper
• Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice

  2008cited by this paper
• Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury.

  2008cited by this paper
• Urotensin II: A New Pharmacologic Target in the Treatment of Cardiovascular Disease

  2008cited by this paper
• Urotensin-II and cardiovascular remodeling.

  2008cited by this paper
• New sst4/5-selective somatostatin peptidomimetics based on a constrained tryptophan scaffold.

  2007cited by this paper
• The involvement of transforming growth factor-beta1 secretion in urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts.

  2007cited by this paper
• Therapeutic potential of blockade of the Urotensin II system in systemic hypertension

  2007cited by this paper
• The conformers of phenylglycine.

  2006cited by this paper
• Urotensin II and renal function in the rat.

  2006cited by this paper
• Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist.

  2006cited by this paper
• Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation.

  2006cited by this paper
• Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease.

  2006cited by this paper
• Expression of urotensin-II in human coronary atherosclerosis.

  2005cited by this paper
• Urotensin-II receptor ligands. From agonist to antagonist activity.

  2005cited by this paper
• Structure–activity relationship study on human urotensin II

  2005cited by this paper
• Exploring Ramachandran and chi space: conformationally constrained amino acids and peptides in the design of bioactive polypeptide ligands.

  2004cited by this paper
• Structure-activity relationships and structural conformation of a novel urotensin II-related peptide.

  2004cited by this paper
• Functional and Binding Characterizations of Urotensin II-Related Peptides in Human and Rat Urotensin II-Receptor Assay

  2003cited by this paper
• Structure–Activity Relationships of Human Urotensin II and Related Analogues on Rat Aortic Ring Contraction

  2003cited by this paper
• Urotensin II Acts Centrally to Increase Epinephrine and ACTH Release and Cause Potent Inotropic and Chronotropic Actions

  2003cited by this paper
• Congestive heart failure and expression of myocardial urotensin II.

  2002cited by this paper
• Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model.

  2002cited by this paper
• A new ligand for the urotensin II receptor

  2002cited by this paper
• Towards control of χ-space: Conformationally constrained analogues of Phe, Tyr, Trp and His

  1999cited by this paper
• beta-Methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activity.

  1997cited by this paper
• Design and synthesis of side-chain conformationally restricted phenylalanines and their use for structure-activity studies on tachykinin NK-1 receptor.

  1994cited by this paper
• Main chain and side chain chiral methylated somatostatin analogs : syntheses and conformational analyses

  1992cited by this paper

• Evidence for heterodimerization and functional interaction of the urotensin II and the angiotensin II type 1 receptors.

  2024cites this paper
• Insights into the Molecular Determinants Involved in Urocontrin and Urocontrin A Action.

  2020cites this paper
• Novel insights into the role of urotensin II in cardiovascular disease.

  2019cites this paper
• Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides.

  2019cites this paper
• Towards Targeting the Urotensinergic System: Overview and Challenges.

  2019cites this paper
• Cyclopropane-Based Peptidomimetics Mimicking Wide-Ranging Secondary Structures of Peptides: Conformational Analysis and Their Use in Rational Ligand Optimization.

  2017cites this paper
• Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors.

  2017cites this paper
• Urotensin core mimics that modulate the biological activity of urotensin-II related peptide but not urotensin-II.

  2017cites this paper
• Urotensin II((4-11)) Azasulfuryl Peptides: Synthesis and Biological Activity.

  2016cites this paper
• Side Chain Cyclized Aromatic Amino Acids: Great Tools as Local Constraints in Peptide and Peptidomimetic Design.

  2016cites this paper
• Blocking of urotensin receptors as new target for treatment of carrageenan induced inflammation in rats.

  2016cites this paper
• International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function

  2015influential citation
• Design of a truncated cardiotoxin-I analogue with potent insulinotropic activity.

  2014cites this paper